Lifco AB has acquired a majority stake in Rhein83 Srl
Lifco AB has acquired a majority stake in the Italian dental company Rhein83 Srl. Financial details have not been disclosed.
Lifco acquires and develops market-leading niche operations with the potential to deliver sustainable profit growth and strong cash flows. The group is listed on Nasdaq Stockholm and has three business areas: dental, demolition & tools and systems solutions. The company has a clear corporate philosophy which implies a long-term perspective, focus on profits and a highly decentralized organization. As of today, the investment group controls circa140 companies in 30 countries, generating revenues of over US$1 billion.
Established in 1983 and located in Bologna, Italy, Rhein83 has innovated the dental market with the introduction of elastic spherical attachments (previously were only metallic) for dental implants. The company's technology is highly recognized and appreciated worldwide.
Oaklins' team in Italy advised the buyer in this transaction.
Ingvar Ljungqvist
Head of Acquisitions, Lifco AB
Prata med transaktionsteamet
Relaterade transaktioner
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Lär dig merbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Lär dig merBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Lär dig mer